Geron stocks.

John Scarlett GERN stock SEC Form 4 insiders trading. John has made over 2 trades of the Geron stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,340,000 units of GERN stock worth $2,010,000 on 8 February 2023.. The largest trade he's ever made was exercising 1,340,000 units of Geron stock …Ms. Bloom GERN stock SEC Form 4 insiders trading. Olivia has made over 8 trades of the Geron stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 400,000 units of GERN stock worth $604,000 on 8 February 2023.. The largest trade she's ever made was exercising 400,000 units of Geron stock on 8 …View Geron Corporation GERN investment & stock information. Get the latest Geron Corporation GERN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Geron Corporation (GERN 3.45%), Arena Pharmaceuticals , and Heron Therapeutics (HRTX-6.54%) skyrocketed more than 30% this week, with one of the stocks turning in an especially impressive performance.

Hailshadow/iStock via Getty Images. Geron Corporation ( NASDAQ: GERN) announced on Monday new data from its Phase 3 portion of the Phase 2/3 IMerge trial for lead candidate imetelstat in ...Jan 27, 2023 · Geron (GERN) closed the most recent trading day at $3.34, moving -0.89% from the previous trading session. This change lagged the S&P 500's 0.25% gain on the day. At the same time, the Dow added 0 ... Common Stock, $0.001 par value. GERN. The Nasdaq Stock Market LLC. Securities registered pursuant to Section 12(g) of the Act: None.

Geron GERN has high hopes for drug candidates in its pipeline. It had a successful phase 3 clinical trial with its Imetelstat medication, which would be used to treat lower-risk myelodysplastic syndromes. Geron stock is having an up-and-down start to 2023, rising as high as 40% but then failing to hold on to its gains.

Geron Corporation announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs).In addition, Geron has granted the underwriters a 30-day option to purchase up to an additional 12,131,444 shares of its common stock, less underwriting discounts and commissions.Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives through the unique mechanism of action of telomerase inhibition. Our first-in-class telomerase inhibitor, imetelstat, …According to 4 stock analysts, the average 12-month stock price forecast for Geron stock is $4.75, which predicts an increase of 141.12%. The lowest target is $4.00 and the highest is $6.00. On average, analysts rate Geron stock as a strong buy.

Sep 12, 2023 · Geron Corporation ( NASDAQ: GERN) added ~9% on Tuesday in the morning hours after Goldman Sachs upgraded the biotech to Buy from Neutral, citing a potential FDA approval for its blood cancer ...

In reaction to the development, Geron stock slumped about 63 percent Sept. 27. A Needham analyst sees the return of imetelstat as creating a buying opportunity in Geron. The Analyst.

Citigroup Inc. reduced its position in shares of Geron Co. (NASDAQ:GERN – Free Report) by 64.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).The institutional investor owned 529,339 shares of the biopharmaceutical company’s stock after selling 951,365 shares during the …Real time Geron (GERN) stock price quote, stock graph, news & analysis. Stock Price Statistics The stock price has decreased by -16.81% in the last 52 weeks. The beta is 0.82, so Geron's price volatility has been lower than the market average.NVIDIA Corporation Common Stock. $455.72 -6.69 -1.45%. Geron Corporation Common Stock (GERN) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Find the latest Geron Corporation (GERN) stock quote, history, news and other vital information to help you with your stock trading and investing.To: All persons who purchased Geron Corporation (“Geron”) common stock during the period from March 19, 2018, to September 26, 2018, inclusive (the “Class Period”), and who were damaged ...

Dividends on Geron stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... Geron Corporation, a late-stage clinical biopharmaceutical company, ...Summary. Geron will report Q1 2023 earnings this Thursday 11th May. The company may be close to winning a first FDA approval for a drug in its >30-year history. Imetelstat is a differentiated drug ...Sep 16, 2022 · Not surprisingly, Geron stock, which had risen to a price of >$6 on the positive IMerge study news, collapsed to <$1. The stock price remained depressed throughout 2020 and 2021, but Geron did not ... Dec 1, 2023 · Geron has generated ($0.34) earnings per share over the last year ( ($0.34) diluted earnings per share). Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share. Geron has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, 2024 based ... Geron has another set of issues being raised against it by some recent articles. Flexion is up slightly on phase 3b data. ... Hence, I avoid Geron. Stocks in News: Analysis of FLXN, AXSM.

Looking at Geron's most recent earnings report, as of June 30, 2023, the company had $400.2M in cash and equivalents. In Q2 2023, Geron received $17.8M from cash exercises of warrants and may ...01/04/2023. Download this Press Release. FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to ...

Geron shares are trading up 3.14% at $1.97 at the time of this writing on Wednesday morning. Since the current price is $1.97, this makes Aggarwal's 200,000 shares worth $393,980. Now trade stocks ...Dec 1, 2023 · Geron has generated ($0.34) earnings per share over the last year ( ($0.34) diluted earnings per share). Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share. Geron has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, 2024 based ... Geron has seen some favorable Phase II data from their core product pipeline, which helped drive their share price up by ~20% over the past few months. As they continue to believe final results ...Geron Corp GERN Morningstar Rating Unlock Stock XNAS Rating as of Dec 1, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating Performance...PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase inhibitor, was evaluated in patients with intermediate-2 or high-risk myelofibrosis R/R to …Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Geron Corporation ( NASDAQ: GERN) has been a broadly upbeat stock since January, when it announced IMerge Phase 3 data in lower-risk myelodysplastic syndromes ('MDS'). The data, which I covered in ...

Find the latest Geron Corporation (GERN) stock quote, history, news and other vital information to help you with your stock trading and investing.

Geron shares are trading up 3.14% at $1.97 at the time of this writing on Wednesday morning. Since the current price is $1.97, this makes Aggarwal's 200,000 shares worth $393,980. Now trade stocks ...

il y a 13 heures ... Geron is a late-stage clinical biopharmaceutical company pursuing ... Stocks Could Thrive Under 'Higher for Longer' Interest Rates. Sarah ...Looking at Geron's most recent earnings report, as of June 30, 2023, the company had $400.2M in cash and equivalents. In Q2 2023, Geron received $17.8M from cash exercises of warrants and may ...I think Geron has the best short fuse risk-reward ratio of any stock I know. $10 by 10/10 - that is the clear diktat from my latest seance. Nonetheless, it carries great risk. Do not invest more ...Geron&#39;s stock rises on positive Phase 3 trial results for its myelodysplastic syndrome drug, imetelstat, potentially improving treatment for certain...new york, may 01, 2023 (globe newswire) -- united states district court <stronDec 30, 2022 · See GERN Report. Geron Corporation ( GERN) is near the top in its industry group according to InvestorsObserver. GERN gets an overall rating of 80. That means it scores higher than 80 percent of stocks. Geron Corporation gets a 95 rank in the Biotechnology industry. Biotechnology is number 48 out of 148 industries. GERN has an Overall Score of 80. What this means: InvestorsObserver gives Geron Corp (GERN) an overall rank of 47, which is below average. Geron Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 47 means that 53% of stocks appear more favorable to our system.Geron stock has received a consensus rating of buy. The average rating score is and is based on 14 buy ratings, 1 hold ratings, and 0 sell ratings. What was the 52-week low for Geron stock? Headline. Geron (GERN) Stock Surges After FDA Removes Full Clinical Hold on Imetelstat Application. thestreet.com - November 21 at 8:55 PM. Geron to Participate at Upcoming Investor Conferences in November. finance.yahoo.com - November 7 at 8:02 PM. Geron’s Growth Prospects: Expanding Commercial Team, Imetelstat Development, and Financial ...GERN stock analysis and financial data, including key statistics and ratios, valuations, historical price and financial performance of Geron.

May 11, 2023 · Geron (GERN 1.03%) Q1 ... 10 stocks we like better than Geron When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ... See the company profile for Geron Corporation (GERN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...FOSTER CITY, Calif., November 07, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: Find the latest Geron Corporation (GERN) stock quote, history, news ... Geron Corporation ( NASDAQ: GERN) announced Tuesday that the U.S. FDA accepted its marketing application for the blood cancer therapy imetelstat, under standard review with a Prescription Drug ...Instagram:https://instagram. stocktwits spcefutures trading strategytrading practice sitesmattel stocks Jul 18, 2023 · Recent developments: Geron's stock rose after announcing the New Drug Application [NDA] submission of imetelstat for the treatment of "transfusion-dependent anemia in adult patients with low- to ... Open Int (30-Day): The average total open interest for all option contracts (across all expiration dates) for the last 30 days. Geron Corp stocks price quote with latest real … aclhf stockbest investing magazine Jun 18, 2021 · Why Geron Stock Is Soaring Today. By Keith Speights – Jun 18, 2021 at 11:40AM ... Shares of Geron (GERN 2.09%) were trading up by 35.8% as of 11:33 a.m. EDT on Friday. The big jump came after ... If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets. the merge nft Geron Corp Stock Forecast, Predictions & Price Target. Add to Watchlist. Overview Forecast. Earnings Dividend Ownership. Analyst price target for GERN. All Analysts Top Analysts. Based on 3 analysts offering 12 month price targets for Geron Corp. Min Forecast. $4.00 +109.42%. Avg Forecast. $4.67 +144.35%.Shares of Geron Corporation ( NASDAQ: GERN) reached the lowest level since late December on Tuesday after Goldman Sachs launched its coverage with a Neutral view noting that the stock already ...Summary. Geron will report Q1 2023 earnings this Thursday 11th May. The company may be close to winning a first FDA approval for a drug in its >30-year history. Imetelstat is a differentiated drug ...